title: Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989.
abstract: A total of 3303 healthy children and adolescents, aged 12 months to 17 years, were vaccinated with one of five production lots of a live attenuated varicella vaccine (VARIVAX) containing 1000 to 1625 plaque-forming units per dose. The vaccine was generally well tolerated. Ninety-six percent (2381/2475) of vaccinees responded to vaccination by producing antibody as measured by a glycoprotein-based enzyme-linked immunosorbent assay; 99% (569/576) of those tested maintained antibody at 1 year following vaccination. The incidence of varicella following household exposure in vaccinees was approximately 12%; household contact historically results in 87% infection. Nearly all of the vaccinees who had varicella after vaccination had a clinically modified disease.
authors.affiliation: Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, Pennsylvania 19486.
authors.forename: C J
authors.initials: CJ
authors.lastname: White
authors.forename: B J
authors.initials: BJ
authors.lastname: Kuter
authors.forename: C S
authors.initials: CS
authors.lastname: Hildebrand
authors.forename: K L
authors.initials: KL
authors.lastname: Isganitis
authors.forename: H
authors.initials: H
authors.lastname: Matthews
authors.forename: W J
authors.initials: WJ
authors.lastname: Miller
authors.forename: P J
authors.initials: PJ
authors.lastname: Provost
authors.forename: R W
authors.initials: RW
authors.lastname: Ellis
authors.forename: R J
authors.initials: RJ
authors.lastname: Gerety
authors.forename: G B
authors.initials: GB
authors.lastname: Calandra
mesh_terms: D000293:Adolescent; D000914:Antibodies, Viral / Q000097:blood*; D002644:Chickenpox / Q000517:prevention & control*; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014765:Viral Vaccines